What is this study about?
This trial is testing an experimental drug, nelotanserin, to determine if it is safe and effective in treating visual hallucinations in people with Lewy body dementia.
What is involved?
The study begins with a double-blind, placebo controlled phase, which means neither the researcher nor the person in the study will know who is getting the investigational medication, nelotanserin, or a placebo. Then, the study will continue with an open-label extension, in which all participants will receive the investigational medicine.
Participants in this study will attend an initial screening visit plus another 7 visits over approximately 18 weeks. Transportation assistance to and from study visits may be available.
Who can participate?
An individual with LBD may be able to take part in the trial if he/she:
- Is between the ages of 50 and 85
- Has been diagnosed with dementia with Lewy bodies (DLB) or Parkinson’s disease dementia (PDD)
- Has frequent visual hallucinations
Axovant Sciences, Ltd.
Still have questions?
For more information about this clinical trial, please contact Axovant Sciences at (919) 425-0709.